Soluble recombinant CR2 (CD21) inhibits Epstein-Barr virus infection
- PMID: 2154612
- PMCID: PMC249254
- DOI: 10.1128/JVI.64.3.1348-1352.1990
Soluble recombinant CR2 (CD21) inhibits Epstein-Barr virus infection
Abstract
Epstein-Barr virus (EBV), an oncogenic herpesvirus of humans, displays selective tropism for B lymphocytes and epithelial cells. EBV tropism is thought to be determined in part by a unique host cell receptor termed CR2 (CD21). Although previous studies have demonstrated that CR2 mediates EBV binding to B cells, its role in initiating EBV infection and B-cell transformation is less certain. In the studies reported here, soluble recombinant CR2 was shown to cause substantial inhibition of EBV infection of B cells in vitro, indicating that CR2 binding initiates EBV infection. Soluble CR2 may represent a therapeutic agent for acute and chronic EBV infections in humans.
Similar articles
-
Stable transfection of Epstein-Barr virus (EBV) nuclear antigen 2 in lymphoma cells containing the EBV P3HR1 genome induces expression of B-cell activation molecules CD21 and CD23.J Virol. 1990 Mar;64(3):1002-13. doi: 10.1128/JVI.64.3.1002-1013.1990. J Virol. 1990. PMID: 2154588 Free PMC article.
-
Structural requirements for C3d,g/Epstein-Barr virus receptor (CR2/CD21) ligand binding, internalization, and viral infection.J Biol Chem. 1990 Jul 25;265(21):12293-9. J Biol Chem. 1990. PMID: 1695627
-
Interaction between Epstein-Barr virus and a T cell line (HSB-2) via a receptor phenotypically distinct from complement receptor type 2.Eur J Immunol. 1992 May;22(5):1123-31. doi: 10.1002/eji.1830220504. Eur J Immunol. 1992. PMID: 1315687
-
Immunobiology of CR2, the B lymphocyte receptor for Epstein-Barr virus and the C3d complement fragment.Annu Rev Immunol. 1988;6:85-113. doi: 10.1146/annurev.iy.06.040188.000505. Annu Rev Immunol. 1988. PMID: 2838050 Review. No abstract available.
-
Structure and function of the complement receptors, CR1 (CD35) and CR2 (CD21).Adv Immunol. 1989;46:183-219. doi: 10.1016/s0065-2776(08)60654-9. Adv Immunol. 1989. PMID: 2551147 Review. No abstract available.
Cited by
-
Molecular basis of the interaction between complement receptor type 2 (CR2/CD21) and Epstein-Barr virus glycoprotein gp350.J Virol. 2008 Nov;82(22):11217-27. doi: 10.1128/JVI.01673-08. Epub 2008 Sep 10. J Virol. 2008. PMID: 18786993 Free PMC article.
-
Inhibition of Epstein-Barr virus infection in vitro and in vivo by soluble CR2 (CD21) containing two short consensus repeats.J Virol. 1991 Jul;65(7):3559-65. doi: 10.1128/JVI.65.7.3559-3565.1991. J Virol. 1991. PMID: 1645784 Free PMC article.
-
Epstein-Barr virus, infectious mononucleosis, and posttransplant lymphoproliferative disorders.Transplant Sci. 1994 Sep;4(1):61-79. Transplant Sci. 1994. PMID: 7804700 Free PMC article. Review.
-
Epstein-Barr viruses that express a CD21 antibody provide evidence that gp350's functions extend beyond B-cell surface binding.J Virol. 2010 Jan;84(2):1139-47. doi: 10.1128/JVI.01953-09. Epub 2009 Nov 4. J Virol. 2010. PMID: 19889766 Free PMC article.
-
The soluble form of the EIAV receptor encoded by an alternative splicing variant inhibits EIAV infection of target cells.PLoS One. 2013 Nov 22;8(11):e79299. doi: 10.1371/journal.pone.0079299. eCollection 2013. PLoS One. 2013. PMID: 24278125 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources